BridgeBio Pharma (BBIO) Intangibles (2018 - 2025)
BridgeBio Pharma's Intangibles history spans 7 years, with the latest figure at $28.1 million for Q4 2025.
- On a quarterly basis, Intangibles rose 17.35% to $28.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.1 million, a 17.35% increase, with the full-year FY2025 number at $28.1 million, up 17.35% from a year prior.
- Intangibles hit $28.1 million in Q4 2025 for BridgeBio Pharma, down from $28.8 million in the prior quarter.
- Over the last five years, Intangibles for BBIO hit a ceiling of $46.2 million in Q3 2021 and a floor of $15.0 million in Q4 2021.
- Historically, Intangibles has averaged $27.9 million across 5 years, with a median of $27.9 million in 2025.
- The widest YoY moves for Intangibles: up 91.41% in 2022, down 36.56% in 2022.
- Tracing BBIO's Intangibles over 5 years: stood at $15.0 million in 2021, then soared by 91.41% to $28.7 million in 2022, then dropped by 8.33% to $26.3 million in 2023, then decreased by 9.09% to $23.9 million in 2024, then rose by 17.35% to $28.1 million in 2025.
- Business Quant data shows Intangibles for BBIO at $28.1 million in Q4 2025, $28.8 million in Q3 2025, and $29.5 million in Q2 2025.